Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release formulation of nalbuphine that targets the opioid receptors controlling the cough reflex, for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Nalbuphine, approved for decades as an injectable pain medication, works as a kappa receptor agonist and mu receptor antagonist, which reduces the potential for abuse and provides a safer alternative to traditional opioids. The company owns the worldwide commercial rights to Haduvio and plans to build a specialty sales force targeting pulmonologists and other relevant specialists in the U.S., while pursuing partnerships for international distribution, generating revenue through product sales once regulatory approvals are obtained.